Cash Flow Statement

Cash from Financing Activities Cash from Operations Change in Account Payables Change in Accured Expenses Change in Cash Change in Receivables Depreciation & Amortization (CF)Exchange Rate Effect Free Cash Flow Gains from Investment Securities Gains from Sales and Divestitures Net Cash Flow Net Income Non-cash Items Other Working Capital Changes Other financing activities Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Neuphoria Therapeutics (NEUP) Gains from Sales and Divestitures (2025)

Neuphoria Therapeutics (NEUP) has disclosed Gains from Sales and Divestitures for 1 consecutive years, with $33915.0 as the latest value for Q4 2025.